Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.48 |
| ▸ | SLC47A1 | Q96FL8 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 6/20 | 0.43 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
| ▸ | DPP4 | P27487 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15149727 | 0.82 | ALDH1A1 (0.50) | NPC1ALDH1A1SLC22A2SLC47A1MAPT | |
| SCHEMBL1089252 | 0.82 | ALDH1A1 (0.50) | NPC1ALDH1A1SLC22A2SLC47A1MAPT | |
| SCHEMBL8073575 | 0.82 | ALDH1A1 (0.50) | NPC1ALDH1A1SLC22A2SLC47A1MAPT | |
| SCHEMBL8250495 | 0.81 | DPP4 (0.48) | NPC1ALDH1A1DPP4CYP3A4 | |
| SCHEMBL29201779 | 0.77 | ALDH1A1 (0.51) | NPC1ALDH1A1SLC22A2SLC47A1MAPT | |
| SCHEMBL14673444 | 0.75 | ALDH1A1 (0.44) | NPC1ALDH1A1SLC22A2SLC47A1MAPT | |
| SCHEMBL17628726 | 0.71 | ALDH1A1 (0.39) | NPC1ALDH1A1SLC22A2SLC47A1MAPT | |
| SCHEMBL17628724 | 0.71 | ALDH1A1 (0.39) | NPC1ALDH1A1SLC22A2SLC47A1MAPT | |
| SCHEMBL237472 | 0.70 | SLC22A2 (0.56) | NPC1ALDH1A1SLC22A2SLC47A1MAPT | |
| SCHEMBL182779 | 0.70 | SLC22A2 (0.56) | NPC1ALDH1A1SLC22A2SLC47A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090176853-A1 | Adamantane derivatives | ALCARAZ LILIAN | 2009-07-09 | — | — | US | disclosed |
| US-20080139636-A1 | Adamantane derivatives | ASTRAZENECA AB. | 2008-06-12 | — | — | US | disclosed |
| EP-1862451-A1 | Adamantane derivatives for the treatment of inflammatory diseases | AstraZeneca AB (SE) | 2007-12-05 | — | — | EP | disclosed |
| US-7297818-B2 | Adamantane derivatives | ASTRAZENECA AB (SE) | 2007-11-20 | — | — | US | disclosed |
| EP-1352896-B1 | Adamantane derivatives for the treatment of inflammatory, immune and cardiovascular diseases | ASTRAZENECA AB (SE) | 2007-10-31 | — | — | EP | disclosed |
| US-20070082957-A1 | Adamantane derivatives | ASTRAZENECA AB | 2007-04-12 | — | — | US | disclosed |
| EP-1352897-B1 | Adamantane derivatives for the treatment of inflammatory, immune and cardiovascular diseases | ASTRAZENECA AB (SE) | 2007-01-03 | — | — | EP | disclosed |
| US-7132457-B2 | Adamantane derivatives | ASTRAZENECA AB (SE) | 2006-11-07 | — | — | US | disclosed |
| US-20050049303-A1 | 2-Chloro-5-[3-[(2-hydroxyethyl)amino]propyl]-N-(tricyclo[3.3.1.13,7]dec-1-ylmethyl)-benzamide; preparation from chemical intermediates; use in treating rheumatoid arthritis, chronic obstructive pulmonary disease | ASTRAZENECA AB | 2005-03-03 | — | — | US | disclosed |
| EP-1242364-B1 | ADAMANTANE DERIVATIVES | ASTRAZENECA AB (SE) | 2004-03-17 | — | — | EP | disclosed |
| EP-1352896-A2 | Adamantane derivatives for the treatment of inflammatory, immune and cardiovascular diseases | AstraZeneca AB (SE) | 2003-10-15 | — | — | EP | disclosed |
| EP-1352895-A2 | Adamantane derivatives for the treatment of inflammatory, immune and cardiovascular diseases | AstraZeneca AB (SE) | 2003-10-15 | — | — | EP | disclosed |
| EP-1352897-A2 | Adamantane derivatives for the treatment of inflammatory, immune and cardiovascular diseases | AstraZeneca AB (SE) | 2003-10-15 | — | — | EP | disclosed |
| EP-1242364-A1 | ADAMANTANE DERIVATIVES | AstraZeneca AB (SE) | 2002-09-25 | — | — | EP | disclosed |
| WO-2001044170-A1 | ADAMANTANE DERIVATIVES | ASTRAZENECA AB (SE) | 2001-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070082957-A1 | Adamantane derivatives | ADAM33, ADAM17, BACE1 | NPC1 100/4885ALDH1A1 282/4885SLC22A2 1817/4885 |
| US-20090176853-A1 | Adamantane derivatives | ADAM33, ADAM17, BACE1 | NPC1 111/4885ALDH1A1 328/4885SLC22A2 1926/4885 |
| US-20050049303-A1 | 2-Chloro-5-[3-[(2-hydroxyethyl)amino]propyl]-N-(tricyclo[3.3.1.13,7]dec-1-ylmethyl)-benzamide; preparation from chemical intermediates; use in treating rheumatoid arthritis, chronic obstructive pulmonary disease | HRH1, HRH2, HRH4 | NPC1 1670/4885ALDH1A1 126/4885SLC22A2 3022/4885 |
| US-20080139636-A1 | Adamantane derivatives | ADAM33, ADAM17, BACE1 | NPC1 111/4885ALDH1A1 328/4885SLC22A2 1926/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.